Reviewing Genocea Biosciences (NASDAQ:GNCA) and Aziyo Biologics (NASDAQ:AZYO)
Reviewing Genocea Biosciences (NASDAQ:GNCA) and Aziyo Biologics (NASDAQ:AZYO)
Genocea Biosciences (NASDAQ:GNCA – Get Rating) and Aziyo Biologics (NASDAQ:AZYO – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.
基因生物科学(纳斯达克：GNCA-GET评级)和阿齐约生物(纳斯达克：AZYO-GET评级)都是小盘医疗公司，但哪只股票更好？我们将根据两家公司的股息、机构所有权、收益、盈利能力、分析师建议、风险和估值来比较它们的实力。
Analyst Ratings
分析师评级
This is a breakdown of current ratings and recommmendations for Genocea Biosciences and Aziyo Biologics, as reported by MarketBeat.com.
据MarketBeat.com报道，这是对Genocea Biosciences和Aziyo Biologics的当前评级和推荐的细分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genocea Biosciences | 0 | 2 | 0 | 0 | 2.00 |
| Aziyo Biologics | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Genocea生物科学 | 0 | 2 | 0 | 0 | 2.00 |
| Aziyo生物制品 | 0 | 0 | 3 | 0 | 3.00 |
Genocea Biosciences presently has a consensus price target of $3.00, suggesting a potential upside of 26,685.71%. Aziyo Biologics has a consensus price target of $12.00, suggesting a potential upside of 83.21%. Given Genocea Biosciences' higher possible upside, analysts clearly believe Genocea Biosciences is more favorable than Aziyo Biologics.
Genocea Biosciences目前的共识目标价为3.00美元，这意味着潜在的上涨幅度为26,685.71%。Aziyo Biologics的共识目标价为12.00美元，暗示潜在上行空间为83.21%。考虑到Genocea Biosciences更有可能的上行空间，分析师们显然认为Genocea Biosciences比Aziyo Biologics更有利。
Risk & Volatility
风险与波动性
Profitability
盈利能力
This table compares Genocea Biosciences and Aziyo Biologics' net margins, return on equity and return on assets.
此表比较了Genocea Biosciences和Aziyo Biologics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
| Aziyo Biologics | -60.68% | -260.23% | -43.50% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Genocea生物科学 | 不适用 | -182.88% | -62.76% |
| Aziyo生物制品 | -60.68% | -260.23% | -43.50% |
Valuation and Earnings
估值和收益
This table compares Genocea Biosciences and Aziyo Biologics' revenue, earnings per share (EPS) and valuation.
此表比较了Genocea Biosciences和Aziyo Biologics的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genocea Biosciences | $1.64 million | 0.40 | -$33.20 million | ($0.61) | -0.02 |
| Aziyo Biologics | $47.39 million | 1.87 | -$24.83 million | ($2.46) | -2.66 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Genocea生物科学 | 164万美元 | 0.40 | -3320万美元 | ($0.61) | -0.02 |
| Aziyo生物制品 | 4739万美元 | 1.87 | -2,483万元 | ($2.46) | -2.66 |
Aziyo Biologics has higher revenue and earnings than Genocea Biosciences. Aziyo Biologics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Aziyo Biologics的收入和收益比Genocea Biosciences更高。Aziyo Biologics的市盈率低于Genocea Biosciences，这表明它目前是两只股票中更负担得起的一只。
Insider and Institutional Ownership
内部人与机构持股
59.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 88.6% of Aziyo Biologics shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 39.9% of Aziyo Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Genocea Biosciences 59.3%的股份由机构投资者持有。相比之下，Aziyo Biologics 88.6%的股份由机构投资者持有。Genocea Biosciences 1.6%的股份由公司内部人士持有。相比之下，Aziyo Biologics 39.9%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一只股票有望实现长期增长。
Summary
摘要
Aziyo Biologics beats Genocea Biosciences on 8 of the 14 factors compared between the two stocks.
在两只股票的14个指标中，Aziyo Biologics在8个指标上击败了Genocea Bioscions。
About Genocea Biosciences
关于Genocea生物科学
(Get Rating)
(获取评级)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
生物制药公司Genocea Biosciences，Inc.发现和开发新的癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。它的产品包括Gen-011，这是一种过继的T细胞疗法，正处于治疗实体肿瘤的1/2a阶段临床试验；以及Gen-009，它是一种新抗原候选疫苗，正处于1/2a阶段的临床试验，提供跨越ATLAS识别的抗肿瘤新抗原的辅助性合成长肽。该公司成立于2006年，总部设在马萨诸塞州剑桥市。
About Aziyo Biologics
关于Aziyo生物制品公司
(Get Rating)
(获取评级)
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Aziyo Biologics，Inc.是一家再生医学公司，专注于再生医疗产品的开发，以满足植入式电子设备/心血管、矫形/脊柱修复和软组织重建市场。它提供CanGaroo，它将信封与抗生素结合在一起，旨在降低电子设备手术植入后的感染风险。该公司还提供心血管产品，如用作心脏内补片或组织修复的质地的ProxiCor；用于新生儿和婴儿修复心包结构的Tyke；以及用于修复或重建周围血管的补丁材料VasCure，包括供心血管、血管和普通外科医生使用的颈动脉、肾、髂骨、股动脉和胫骨血管。此外，它还提供Fibre VBM、Vibone和OsteGro V，这是一种从人体组织衍生的同种异体骨移植，旨在保护和保存天然骨细胞；以及Simpliderm，一种预水HADM，旨在修复或替换受损或不充分的外皮组织。此外，公司还为企业客户提供各种产品的代工服务。它通过其直销队伍、商业合作伙伴和独立销售代理向医院和其他医疗机构销售其产品。该公司成立于2015年，总部设在马里兰州的银泉。
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。